Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

Biogen Inc. BIIB announced that it has dosed the first patient in the phase III study — TOPAZ-1 — that will evaluate its humanized IgG1 monoclonal antibody (mAb) candidate, BIIB059, in patients with active systemic lupus erythematosus (SLE).